DBV Technologies S.A. (DBVT)
NASDAQ: DBVT · Real-Time Price · USD
21.87
-0.21 (-0.95%)
Mar 6, 2026, 4:00 PM EST - Market closed
DBV Technologies Employees
DBV Technologies had 110 employees as of December 31, 2024. The number of employees increased by 5 or 4.76% compared to the previous year.
Employees
110
Change (1Y)
5
Growth (1Y)
4.76%
Revenue / Employee
$47,026
Profits / Employee
-$1,069,513
Market Cap
1.21B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Immatics | 645 |
| EyePoint | 165 |
| Precigen | 143 |
| MoonLake Immunotherapeutics | 130 |
| Inventiva | 84 |
| Taysha Gene Therapies | 73 |
| Savara | 59 |
| AtaiBeckley | 54 |
DBVT News
- 2 days ago - DBV Technologies S.A.: DBV Technologies to Participate in Upcoming March Investor Conferences - Finanz Nachrichten
- 2 days ago - DBV Technologies to Participate in Upcoming March Investor Conferences - GlobeNewsWire
- 3 days ago - DBV Technologies S.A.: Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of February 28, 2026 - Finanz Nachrichten
- 5 days ago - DBV Technologies Peanut Patch Meets Primary Endpoint In Phase 3 VITESSE Study - Nasdaq
- 5 days ago - DBVT Shares Promising Phase 3 Trial Results for Viaskin Peanut - GuruFocus
- 6 days ago - DBV Technologies S.A.: DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting - Finanz Nachrichten
- 6 days ago - DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting - GlobeNewsWire
- 24 days ago - DBV Technologies To Present Additional VITESSE Phase 3 Data In Peanut-Allergic Children - Nasdaq